文献速递前列腺癌

前列腺癌根治术后不良特征辅助治疗的趋势与预测因素:基于CaPSURE注册研究的分析

Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor.
PubMed 文献 · Urology · 2019-05-28

基于CaPSURE注册研究(1990-2017)纳入2209例根治术后不良特征(pT3N0M0和/或切缘阳性)及108例淋巴结阳性(pN1)患者,分析辅助治疗趋势与预测因素。不良特征患者辅助治疗从1990-1994年的13.3%降至2005-2017年的6%或以下(Ptrend<.001);切缘阳性pT3a和pT3b患者接受辅助治疗的比值比分别为4.13和7.09。不良特征类型与前列腺癌特异性死亡率在单因素分析中相关(log-rank P<.01),但在竞争风险回归中不相关(P=.06)。

要点

  • 不良特征患者辅助治疗比例从13.3%(1990-1994)降至6%或以下(2005-2017,Ptrend<.001)。
  • 切缘阳性pT3a和pT3b患者接受辅助治疗的OR分别为4.13和7.09。
  • 不良特征类型与前列腺癌特异性死亡率在竞争风险回归中无显著关联(P=.06)。

核心结论

  • 根治术后不良特征患者辅助治疗比例下降,且提供者对不同不良特征类型的处理不一致,尽管指南有广泛推荐。

研究设计与样本

  • 基于CaPSURE注册研究(1990-2017)的回顾性分析,纳入2209例根治术后不良特征(pT3N0M0和/或切缘阳性)及108例淋巴结阳性(pN1)患者。

主要发现

  • 2209例不良特征且pN0患者中,89例(4.0%)接受单纯辅助外照射放疗,82例(3.7%)接受单纯雄激素剥夺治疗,30例(1.4%)接受外照射放疗联合雄激素剥夺治疗。
  • 108例pN1患者中,54例(50%)接受雄激素剥夺治疗(联合或不联合外照射放疗)。
  • 不良特征患者辅助治疗比例从13.3%(1990-1994)降至6%或以下(2005-2017,Ptrend<.001)。
  • 与切缘阴性pT3a患者相比,切缘阳性pT3a患者接受辅助治疗的比值比为4.13(95%CI 2.21-7.73,P<.01),切缘阳性pT3b患者为7.09(95%CI 3.66-1.73,P<.01)。
  • 不良特征类型与前列腺癌特异性死亡率在单因素分析中相关(log-rank P<.01),但在竞争风险回归中不相关(P=.06)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine trends and predictors of adjuvant therapy in patients with adverse features at radical prostatectomy (RP), and to investigate the associations of adjuvant therapy and adverse feature type with survival. METHODS: From the Cancer of the Prostate Strategic Urologic Research Endeavor registry (1990-2017), 2209 men with adverse features (pT3N0M0 disease and/or positive surgical margins), and 108 men with positive lymph nodes (pN1) at RP were identified. Temporal trends were evaluated, and predictors of adjuvant therapy were assessed with multivariate logistic regression. Kaplan-Meier analysis and competing risks regression were used to test cumulative incidence and risk of all-cause and prostate cancer-specific mortality. RESULTS: Of 2209 men with adverse features and pN0 disease, 89 (4.0%), 82 (3.7%), and 30 (1.4%) received adjuvant external beam radiation therapy (ERBT) alone, androgen deprivation therapy (ADT) alone, or combined EBRT and ADT, respectively. Of 108 men with pN1 disease, 54 (50%) received ADT with or without EBRT. Adjuvant treatment for patients with adverse features decreased from 13.3% (1990-1994) to 6% or less (2005-2017, Ptrend <.001). Patients with margin positive pT3a (odds ratio 4.13; 95% confidence interval 2.21-7.73; P<.01) and margin positive pT3b disease (odds ratio 7.09; 95% confidence interval 3.66-1.73; P<.01) had greater odds of receiving adjuvant therapy compared to patients with margin negative pT3a disease. Adverse feature type was associated with prostate cancer-specific mortality in univariate analysis (log-rank P <.01), but not in competing risks regression (P= .06). CONCLUSION: Adjuvant therapy declined for men with adverse features at RP. Providers do not treat all adverse feature types the same way, despite broad treatment recommendations in guidelines.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Balakrishnan AS, Zhao S, Cowan JE, et al. Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 2019. PMID: 31150694. doi:10.1016/j.urology.2019.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。